Immorna Biotherapeutics

Executive Summary

Immorna Biotherapeutics is a global biotechnology company leveraging its proprietary circular RNA (circRNA) and lipid nanoparticle (LNP) delivery platform to develop next-generation vaccines and therapeutics. Unlike linear mRNA, circRNA is more stable and can produce proteins for longer durations, potentially enabling lower dosing and more durable immune responses. The company focuses on infectious disease vaccines (including potential COVID-19 and influenza candidates), cancer immunotherapies, and protein replacement therapies for rare diseases. Founded in 2019 and headquartered in Jinan, China, Immorna has grown to 200–500 employees and aims to address significant unmet medical needs globally. Currently in the preclinical stage, Immorna is advancing its lead programs toward IND-enabling studies. Its circRNA platform has the potential to overcome key limitations of conventional mRNA technologies, such as stability and immunogenicity. While the company faces typical early-stage risks, its differentiated platform and broad pipeline position it as a promising player in the RNA therapeutics space. Upcoming milestones include IND filings for lead vaccine candidates and potential partnerships to support clinical development and manufacturing scale-up.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Vaccine Candidate70% success
• Q3 2026Partnership or Licensing Deal for circRNA Platform50% success
• Q2 2026Publication of Preclinical Data in Peer-Reviewed Journal80% success